DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L. et al.
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
Lancet Oncol 2019;
20: 1239-51
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.